Herpes Simplex Virus Assay, Sample-to-Answer Instrument Get FDA Clearance
By LabMedica International staff writers Posted on 14 Nov 2018 |
Image: The HSV2 ELITe MGB Kit is a real-time PCR assay designed for the detection and quantification of type 2 herpes simplex virus DNA (Photo courtesy of EliTech Group).
Herpes simplex virus 2 (HSV2) is a widespread herpes virus, usually sexually transmitted and responsible for genital herpes. Herpes simplex virus 1 (HSV1) is a common virus life-long established in the peripheral nervous system.
A sample-to-results diagnostic instrument and an assay to detect and differentiate herpes simplex viruses 1 and 2 have received 510(k) clearance. The instrument and assay are now commercially available in the USA. The instrument integrates extraction, amplification, and results interpretation, and is also an open platform compatible with commonly used fluorescent probes. It contains 12 independent thermal cyclers that can run different polymerase chain reaction (PCR) profiles in each run, with six detection channels for multiplex detection. It can also run multiple different assays from a single sample tube.
The ELITe MGB HSV 1&2 Assay (EliTech Group, South Logan, UT, USA) is cleared for use by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) on swab specimens from cutaneous or mucocutaneous lesions in symptomatic patients with cold sores or genital herpes. The diagnostic instrument, called the Elite InGenius, is a fully automated benchtop instrument that performs real-time PCR-based testing on 12 tests in a run, requiring two minutes of hands-on time per sample.
The Elite InGenius instrument can be used in various operational modes, including extraction-only, amplification-only, or full-processing extraction, amplification, and result analysis with melt curve analysis capability. It was introduced as a CE-IVD marked instrument in 2015 with a core menu of transplant monitoring assays. The firm also currently markets a menu of CE-marked molecular diagnostics kits for detecting hospital-acquired infections, sexually transmitted diseases, respiratory infections, bacterial and viral meningitis. In addition, the EliTech Group manufactures and distributes diagnostic products for clinical chemistry, microbiology, and molecular biology.
A sample-to-results diagnostic instrument and an assay to detect and differentiate herpes simplex viruses 1 and 2 have received 510(k) clearance. The instrument and assay are now commercially available in the USA. The instrument integrates extraction, amplification, and results interpretation, and is also an open platform compatible with commonly used fluorescent probes. It contains 12 independent thermal cyclers that can run different polymerase chain reaction (PCR) profiles in each run, with six detection channels for multiplex detection. It can also run multiple different assays from a single sample tube.
The ELITe MGB HSV 1&2 Assay (EliTech Group, South Logan, UT, USA) is cleared for use by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) on swab specimens from cutaneous or mucocutaneous lesions in symptomatic patients with cold sores or genital herpes. The diagnostic instrument, called the Elite InGenius, is a fully automated benchtop instrument that performs real-time PCR-based testing on 12 tests in a run, requiring two minutes of hands-on time per sample.
The Elite InGenius instrument can be used in various operational modes, including extraction-only, amplification-only, or full-processing extraction, amplification, and result analysis with melt curve analysis capability. It was introduced as a CE-IVD marked instrument in 2015 with a core menu of transplant monitoring assays. The firm also currently markets a menu of CE-marked molecular diagnostics kits for detecting hospital-acquired infections, sexually transmitted diseases, respiratory infections, bacterial and viral meningitis. In addition, the EliTech Group manufactures and distributes diagnostic products for clinical chemistry, microbiology, and molecular biology.
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders